{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma+%28Hodgkin%27s+and+Non-Hodgkin%27s%29&page=8", "query": { "condition": "Lymphoma (Hodgkin's and Non-Hodgkin's)", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 881, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma+%28Hodgkin%27s+and+Non-Hodgkin%27s%29&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma+%28Hodgkin%27s+and+Non-Hodgkin%27s%29&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T08:06:30.409Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00109356", "title": "Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Leukemia" ], "interventions": [ { "name": "AQ4N (Chemotherapy)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novacea", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2005-03", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2007-05-07", "last_synced_at": "2026-10-15T08:06:30.409Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00109356" }, { "nct_id": "NCT00427557", "title": "Cellular Therapy With Cord Blood Cells", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Leukemia", "Lymphoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Umbilical Cord Blood", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Infusion", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "80 Years", "sex": "ALL", "summary": "Up to 80 Years" }, "enrollment_count": 31, "start_date": "2006-10", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2012-05-28", "last_synced_at": "2026-10-15T08:06:30.409Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00427557" }, { "nct_id": "NCT00186589", "title": "90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Blood and Marrow Transplant (BMT)" ], "interventions": [ { "name": "90Y Ibritumomab tiuxetan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2004-05", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2012-06-06", "last_synced_at": "2026-10-15T08:06:30.409Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00186589" }, { "nct_id": "NCT00577161", "title": "Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "fludarabine and rituximab", "type": "DRUG" }, { "name": "fludarabine, rituximab, pixantrone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2007-09", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2020-10-05", "last_synced_at": "2026-10-15T08:06:30.409Z", "location_count": 8, "location_summary": "Muscle Shoals, Alabama • Oxnard, California • Jefferson City, Missouri + 5 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Oxnard", "state": "California" }, { "city": "Jefferson City", "state": "Missouri" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Albany", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00577161" }, { "nct_id": "NCT00691210", "title": "Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin's Disease", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Vorinostat", "type": "DRUG" }, { "name": "Niacinamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2008-06", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2020-11-20", "last_synced_at": "2026-10-15T08:06:30.409Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00691210" }, { "nct_id": "NCT01421524", "title": "Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Lymphoma, Large B-Cell, Diffuse", "Pleiotropic Pathway Modifier", "Glioblastoma", "Lymphoma", "Primary Central Nervous System Lymphoma" ], "interventions": [ { "name": "CC-122", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 271, "start_date": "2011-09-12", "completion_date": "2023-11-21", "has_results": false, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-10-15T08:06:30.409Z", "location_count": 17, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01421524" }, { "nct_id": "NCT02238522", "title": "Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoproliferative Malignancies", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "ZEN003365", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zenith Epigenetics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-10", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2014-11-13", "last_synced_at": "2026-10-15T08:06:30.409Z", "location_count": 4, "location_summary": "St Louis, Missouri • New York, New York • Springfield, Oregon + 1 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Springfield", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02238522" }, { "nct_id": "NCT05092451", "title": "Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-Cell Lymphoma", "Myelodysplastic Syndromes (MDS)", "Acute Myeloid Leukemia (AML)", "Multiple Myeloma", "Plasma Cell Leukemia", "Hodgkin Lymphoma", "T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia", "Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia", "Blastic Transformation of Chronic Myeloid Leukemia", "Germ Cell Tumors" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "CAR.70/IL15-transduced CB-NK cells", "type": "DRUG" }, { "name": "Fludarabine phosphate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "12 Years to 80 Years" }, "enrollment_count": 80, "start_date": "2022-11-01", "completion_date": "2030-08-31", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-15T08:06:30.409Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05092451" }, { "nct_id": "NCT00323323", "title": "CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "CHOP", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Plasma Samples", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2004-03", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2017-01-20", "last_synced_at": "2026-10-15T08:06:30.409Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00323323" }, { "nct_id": "NCT00383097", "title": "Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkins Lymphoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES", "type": "GENETIC" }, { "name": "LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 6, "start_date": "2006-09", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2012-05-24", "last_synced_at": "2026-10-15T08:06:30.409Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00383097" } ] }